scholarly article | Q13442814 |
P50 | author | Steven Rosenberg | Q2347448 |
P2093 | author name string | Sachs D | |
Shiloni E | |||
Eisenthal A | |||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cytotoxicity | Q246181 |
P304 | page(s) | 1992-1998 | |
P577 | publication date | 1987-03-01 | |
P1433 | published in | Journal of Immunology | Q3521441 |
P1476 | title | Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2 | |
P478 | volume | 138 |
Q33370628 | A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group |
Q37702283 | Anti-GD2 antibody therapy for GD2-expressing tumors |
Q70541113 | Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells |
Q40697616 | Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs |
Q55120894 | Combination therapy with antibody and interleukin-2 gene transfer against multidrug-resistant cancer cells. |
Q68390239 | Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma |
Q41586289 | Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro |
Q68872691 | Effect of recombinant human tumor necrosis factor alpha on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules |
Q67905595 | Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells |
Q37431356 | Immune therapies for neuroblastoma |
Q68888663 | Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2 |
Q55004458 | Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. |
Q67685133 | Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody |
Q34377018 | Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis |
Q54313350 | Monoclonal anti-P-glycoprotein antibody-dependent killing of multidrug-resistant tumor cells by human mononuclear cells. |
Q33718831 | Monoclonal antibody-directed cytotoxic therapy: potential in malignant diseases of aging |
Q33363235 | Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients |
Q54977928 | Release of esterase from murine lymphokine-activated killer cells in antibody-dependent cellular cytotoxic reaction. |
Q34186886 | The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma |
Q39512710 | The development of new immunotherapies for the treatment of cancer using interleukin-2. A review |
Q42183479 | Tumoricidal activation of murine resident peritoneal macrophages on pancreaticcarcinoma by interleukin-2 and monoclonal antibodies. |
Q69674191 | Use of the subrenal capsule assay to measure antibody-dependent, cell-mediated cytotoxicity against head and neck tumors |
Search more.